Company: AZN
Filing Date: 2025-12-16
Form Type: 6-K
Source: 0001654954-25-013974
Chunk: 5

Company: ASTRAZENECA PLC
Filing Date: 2025-12-16
Form: 6-K
Chunk 5
---
 patients with systemic lupus erythematosus: results from the systemic lupus international collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis . 2015;74:1706-1713.

5. Guéry JC. Why is systemic lupus erythematosus more common in women? Joint Bone Spine . 2019;86(3):297-299.

6. American College of Rheumatology. 2025 American College of Rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus (SLE). Available at: lupus-guideline-sle-2025.pdf . [Last accessed: December 2025].

7. Fanouriakis A, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis . 2024;83:15-29.

8. Kaul A, et al. Systemic lupus erythematosus. Nat Rev Dis Primers . 2016;2:16039.

9. Barber MRW, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol . 2021;17(9):515-532.

10. Apostolopoulos D and Morand EF. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford) . 2017;56(Suppl 1):i114-22.

11. Ji L, et al. Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual. Rheumatology . 2021;60:5517-26.

12. Lateef A and Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther . 2012;14(Suppl 4):S4.

13. Morand E, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med . 2020;382(3):211-221.

14. Furie R, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol . 201